To The Moon

This article was automatically generated using Dow Jones technology.Shares of Invesco QQQ Trust Series I rose 0.4% to $738.31 Friday on what proved to be an overall positive trading session for the U.S. stock market, with the S&P 500 Index rising 0.2% to 7,580.06.This was the fund's second consecutive day of gains. The fund's underlying index, the NASDAQ 100 Index , rose 0.4%.Trading volume was 36,862,715, compared to the 65-day average trading volume of 54,126,139.As of May 28, the fund's net asset value totaled $735.59 per share.

At Computex Taipei NVIDIA said it will deploy an RTX Spark “superchip” in PCs to challenge Intel’s dominance. The chip will appear in Dell Technologies and Lenovo laptops and desktops from this...

This article was automatically generated using Dow Jones technology.Shares of Invesco QQQ Trust Series I rose 1.8% to $730.28 Tuesday on what proved to be an overall positive trading session for the U.S. stock market, with the S&P 500 Index rising 0.6% to 7,519.12.This was the fund's fourth consecutive day of gains. The fund's underlying index, the NASDAQ 100 Index , rose 1.8%.Trading volume was 33,515,537, compared to the 65-day average trading volume of 55,522,552.As of May 22, the fund's net asset value totaled $717.55 per share.

In a report released today, Sachin Mittal from DBS maintained a Buy rating on Grab, with a price target of $5.93. According to TipRanks, Mittal is ...

In a report released today, Sachin Mittal from DBS maintained a Buy rating on Grab, with a price target of $5.93. According to TipRanks, Mittal is ...

TD Cowen believes the most notable takeaway from Virgin Galactic’s (SPCE) Q4 report is its target for positive quarterly cash flow in fiscal 2027. ...

CapitaLand India Trust reported an acquisition of 23,846 ordinary voting units by director Tan Soon Neo Jessica, at a consideration of S$0.9729 per unit.Disclaimer: This news brief was created by Public Technologies using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CapitaLand India Trust published the original content used to generate this news brief via Singapore Exchange Limited on March 02, 2026, and is solely responsible for the information contained therein.

Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s Tirzepatide in reducing body weight.